S&P 500   3,906.98 (-1.68%)
DOW   31,617.82 (-0.82%)
QQQ   285.09 (-2.86%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.14 (-4.69%)
NIO   14.86 (-7.13%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.78 (+0.19%)
GE   72.63 (-3.75%)
F   12.32 (-3.98%)
DIS   100.76 (-4.79%)
AMC   10.60 (-8.46%)
PFE   52.84 (-0.08%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,906.98 (-1.68%)
DOW   31,617.82 (-0.82%)
QQQ   285.09 (-2.86%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.14 (-4.69%)
NIO   14.86 (-7.13%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.78 (+0.19%)
GE   72.63 (-3.75%)
F   12.32 (-3.98%)
DIS   100.76 (-4.79%)
AMC   10.60 (-8.46%)
PFE   52.84 (-0.08%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,906.98 (-1.68%)
DOW   31,617.82 (-0.82%)
QQQ   285.09 (-2.86%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.14 (-4.69%)
NIO   14.86 (-7.13%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.78 (+0.19%)
GE   72.63 (-3.75%)
F   12.32 (-3.98%)
DIS   100.76 (-4.79%)
AMC   10.60 (-8.46%)
PFE   52.84 (-0.08%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,906.98 (-1.68%)
DOW   31,617.82 (-0.82%)
QQQ   285.09 (-2.86%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.14 (-4.69%)
NIO   14.86 (-7.13%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.78 (+0.19%)
GE   72.63 (-3.75%)
F   12.32 (-3.98%)
DIS   100.76 (-4.79%)
AMC   10.60 (-8.46%)
PFE   52.84 (-0.08%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. QLGN,AGE,ALIM,CWBR,ACER).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
QLGN
Qualigen Therapeutics
$0.51
-3.7%
$0.61
$0.45
$3.12
$18.02M-0.45954,783 shs200 shs
AGE
AgeX Therapeutics
$0.75
-2.6%
$0.84
$0.52
$1.77
$28.46M1.38208,370 shs200 shs
ALIM
Alimera Sciences
$5.75
+6.5%
$5.45
$3.94
$10.50
$40.27M1.4835,088 shs173 shs
CWBR
CohBar
$0.18
+0.1%
$0.26
$0.18
$2.27
$15.67M2.5546,526 shs1,911 shs
ACER
Acer Therapeutics
$2.24
-0.9%
$2.39
$1.68
$3.77
$34.29M1.28317,999 shs325 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
QLGN
Qualigen Therapeutics
+4.31%0.00%-10.72%-22.91%-72.00%
AGE
AgeX Therapeutics
-2.39%+11.56%-9.29%+11.18%-40.69%
ALIM
Alimera Sciences
+7.78%+27.36%-5.59%+16.13%-44.90%
CWBR
CohBar
-2.70%-9.55%-30.61%-32.58%-86.36%
ACER
Acer Therapeutics
+3.20%+9.71%+3.20%-12.40%-21.80%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
QLGN
Qualigen Therapeutics
1.83 of 5 Stars
3.55.00.00.00.6
AGE
AgeX Therapeutics
0.85 of 5 Stars
0.04.30.00.00.0
ALIM
Alimera Sciences
2.01 of 5 Stars
3.54.30.01.70.6
CWBR
CohBar
2.16 of 5 Stars
3.55.00.01.70.6
ACER
Acer Therapeutics
1.87 of 5 Stars
3.34.70.00.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
QLGN
Qualigen Therapeutics
3.00
Buy$6.501,173.01% Upside
AGE
AgeX Therapeutics
0.00
N/AN/AN/A
ALIM
Alimera Sciences
3.00
Buy$9.5065.22% Upside
CWBR
CohBar
3.00
Buy$2.501,288.12% Upside
ACER
Acer Therapeutics
2.50
Buy$12.00435.71% Upside

Current Analyst Ratings

Latest QLGN, AGE, ALIM, CWBR, and ACER Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2022
ALIM
Alimera Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$10.00 ➝ $8.00
3/15/2022
ACER
Acer Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$12.00
2/25/2022
ALIM
Alimera Sciences
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$14.50 ➝ $11.00
2/25/2022
ALIM
Alimera Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$12.00 ➝ $10.00
(Data available from 5/24/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
QLGN
Qualigen Therapeutics
$5.65M3.19N/AN/A$0.57 per share0.90
AGE
AgeX Therapeutics
$140K203.27N/AN/A($0.31) per share-2.42
ALIM
Alimera Sciences
$59.03M0.68N/AN/A($3.97) per share-1.45
CWBR
CohBar
N/AN/AN/AN/A$0.26 per shareN/A
ACER
Acer Therapeutics
$1.26M27.22N/AN/A($0.66) per share-3.39

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
QLGN
Qualigen Therapeutics
-$17.90MN/A0.00N/AN/A-99.57%-66.80%8/16/2022 (Estimated)
AGE
AgeX Therapeutics
-$8.68MN/A0.00N/A-9,992.47%N/A-346.82%8/10/2022 (Estimated)
ALIM
Alimera Sciences
-$4.37M-$1.01N/AN/AN/A-11.19%N/A-15.00%8/12/2022 (Estimated)
CWBR
CohBar
-$15.48M-$0.21N/AN/AN/AN/A-78.78%-70.82%8/9/2022 (Estimated)
ACER
Acer Therapeutics
-$15.37M-$1.41N/AN/AN/AN/A-1,021.66%-51.25%8/9/2022 (Estimated)

Latest QLGN, AGE, ALIM, CWBR, and ACER Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/20223/31/2022
CWBR
CohBar
-$0.03-$0.04-$0.01N/AN/AN/A    
5/16/20223/31/2022
ACER
Acer Therapeutics
-$0.42-$0.64-$0.22N/AN/AN/A
5/13/20223/31/2022
QLGN
Qualigen Therapeutics
-$0.17-$0.12+$0.05N/AN/AN/A    
5/9/2022Q1 2022
ALIM
Alimera Sciences
-$0.67-$0.85-$0.18-$0.85$13.00 million$11.90 million    
4/1/202212/31/2021
QLGN
Qualigen Therapeutics
-$0.21-$0.20+$0.01N/AN/AN/A
3/29/2022Q4 2021
CWBR
CohBar
N/A-$0.04-$0.04-$0.04N/AN/A    
3/2/2022Q4 2021
ACER
Acer Therapeutics
-$0.08-$0.31-$0.23-$0.31$5.00 million$0.36 million
2/24/2022Q4 2021
ALIM
Alimera Sciences
-$0.38-$0.59-$0.21-$0.59$14.00 million$13.96 million    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/A
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
CWBR
CohBar
N/AN/AN/AN/AN/A
ACER
Acer Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
QLGN
Qualigen Therapeutics
N/A
4.49
4.26
AGE
AgeX Therapeutics
N/A
0.18
0.25
ALIM
Alimera Sciences
N/A
2.04
1.90
CWBR
CohBar
N/A
19.53
15.95
ACER
Acer Therapeutics
N/A
0.85
0.96

Ownership

Institutional Ownership

CompanyInstitutional Ownership
QLGN
Qualigen Therapeutics
7.57%
AGE
AgeX Therapeutics
12.78%
ALIM
Alimera Sciences
40.97%
CWBR
CohBar
22.1%
ACER
Acer Therapeutics
10.34%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
QLGN
Qualigen Therapeutics
3435.30 million33.64 millionNot Optionable
AGE
AgeX Therapeutics
637.94 million35.96 millionNot Optionable
ALIM
Alimera Sciences
1457.00 million6.06 millionOptionable
CWBR
CohBar
1186.98 million60.02 millionNot Optionable
ACER
Acer Therapeutics
3515.31 million12.54 millionNot Optionable

QLGN, AGE, ALIM, CWBR, and ACER Headlines

SourceHeadline
Relief Therapeutics Expands U.S. Commercial TeamRelief Therapeutics Expands U.S. Commercial Team
apnews.com - May 23 at 1:33 AM
Acer Therapeutics (NASDAQ:ACER) Stock Rating Lowered by Zacks Investment ResearchAcer Therapeutics (NASDAQ:ACER) Stock Rating Lowered by Zacks Investment Research
americanbankingnews.com - May 22 at 2:40 AM
Short Interest in Acer Therapeutics Inc. (NASDAQ:ACER) Decreases By 14.5%Short Interest in Acer Therapeutics Inc. (NASDAQ:ACER) Decreases By 14.5%
americanbankingnews.com - May 18 at 2:22 AM
Acer Therapeutics: Q1 Earnings InsightsAcer Therapeutics: Q1 Earnings Insights
benzinga.com - May 16 at 11:10 PM
Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue EstimatesAcer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 16 at 11:10 PM
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate UpdateAcer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 6:10 PM
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue EstimatesOptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 12 at 10:32 AM
Acer Therapeutics reaches agreement with FDA on protocol for phase 3 Edsivo trialAcer Therapeutics reaches agreement with FDA on protocol for phase 3 Edsivo trial
seekingalpha.com - May 9 at 1:51 PM
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsAcer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients
finance.yahoo.com - May 9 at 1:51 PM
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SARelief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
markets.businessinsider.com - May 6 at 1:21 AM
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
dgap.de - May 6 at 1:21 AM
Acer Therapeutics to Participate in H.C. Wainwright Global Investment ConferenceAcer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 5 at 9:46 AM
Acer Therapeutics Inc. (NASDAQ:ACER) Short Interest UpdateAcer Therapeutics Inc. (NASDAQ:ACER) Short Interest Update
americanbankingnews.com - May 1 at 3:28 AM
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. MarketingRelief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
dgap.de - April 26 at 1:11 AM
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for AviptadilRelief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
apnews.com - April 22 at 9:33 AM
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
finance.yahoo.com - April 12 at 8:52 AM
PC sales down 5% in Q1 2022 after two years of growthPC sales down 5% in Q1 2022 after two years of growth
finance.yahoo.com - April 11 at 5:49 PM
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for ...Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for ...
kentuckytoday.com - April 4 at 5:23 PM
Acer Therapeutics Sharply Higher After FDA Breakthrough Therapy DesignationAcer Therapeutics Sharply Higher After FDA Breakthrough Therapy Designation
morningstar.com - April 4 at 12:23 PM
Acer gains on FDA’s Breakthrough status for Edsivo in genetic disorderAcer gains on FDA’s Breakthrough status for Edsivo in genetic disorder
seekingalpha.com - April 4 at 12:23 PM
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos SyndromeAcer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
finance.yahoo.com - April 4 at 12:23 PM
Acer Therapeutics Regains Compliance with Nasdaq Listing StandardAcer Therapeutics Regains Compliance with Nasdaq Listing Standard
finance.yahoo.com - March 31 at 10:01 AM
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseAcer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
finance.yahoo.com - March 30 at 8:59 AM
Relief Therapeutics Reports In Vivo DataRelief Therapeutics Reports In Vivo Data
boersennews.de - March 29 at 10:43 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.